New Analysis From KARDIA-1 Phase 2 Study Presented at the 2024 American College of Cardiology Annual Scientific Session

New Analysis From KARDIA-1 Phase 2 Study Presented at the 2024 American College of Cardiology Annual Scientific Session

A new subgroup analysis from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, was presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session.

Saxena, et al. “Consistent Antihypertensive Efficacy of the RNA Interference Therapeutic Zilebesiran: Subgroup Results from the KARDIA-1 Phase 2 Study in Patients with Hypertension”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.